Quick Answer
Shuttle Pharmaceuticals Holdings, Inc. reported Net Income of -$11.72 million for fiscal year 2025.
Shuttle Pharmaceuticals Holdings, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$11.72M -28.2% |
-$9.14M -38.7% |
-$6.59M -117.7% |
-$3.03M -162.9% |
-$1.15M | — |
| Diluted EPS | -$7.16 +91.3% |
-$82.60 -2239.9% |
-$3.53 -1117.2% |
-$0.29 | — | — |
| Total Assets | $10.48M +318.0% |
$2.51M -57.9% |
$5.95M -31.2% |
$8.65M +1228.0% |
$651.6K | — |
| Cash and Equivalents | $334.0K -82.6% |
$1.92M -25.5% |
$2.58M -69.4% |
$8.42M +1567.6% |
$504.7K | — |
| Stockholders Equity | $2.25M +217.9% |
$709.2K -82.5% |
$4.06M -47.2% |
$7.68M +571.6% |
-$1.63M +3.7% |
-$1.69M |
| R&D Expense | $4.05M +12.0% |
$3.62M +2.9% |
$3.52M +206.2% |
$1.15M +12.4% |
$1.02M | — |
| Operating Income | -$11.92M -54.8% |
-$7.70M -30.6% |
-$5.89M -130.7% |
-$2.55M -46.5% |
-$1.74M | — |
| Shares Outstanding | 2.02M +1140.8% |
163,093 -91.9% |
2.01M -85.2% |
13.60M +46.1% |
9.31M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$2.35M | +38.0% | +36.7% |
| Diluted EPS | September 30, 2025 | -$1.05 | +97.4% | +68.1% |
| Total Assets | September 30, 2025 | $3.54M | +426.0% | -35.6% |
| Cash and Equivalents | September 30, 2025 | $2.09M | +1237.1% | -56.5% |
| Stockholders Equity | September 30, 2025 | $1.39M | +206.0% | -61.3% |
| R&D Expense | September 30, 2025 | $943.5K | -32.6% | -8.0% |
| Operating Income | September 30, 2025 | -$2.27M | +25.7% | +42.0% |
| Shares Outstanding | September 30, 2025 | 1.24M | -58.1% | +15.4% |
- Shuttle Pharmaceuticals Holdings, Inc. reported Net Income of -$11.72 million for fiscal year 2025.
- Shuttle Pharmaceuticals Holdings, Inc. showed a decrease of -28.2% in Net Income compared to the prior fiscal year.
- Shuttle Pharmaceuticals Holdings, Inc. reported Diluted EPS of $7.16 per share (loss) for fiscal year 2025.
- Shuttle Pharmaceuticals Holdings, Inc. showed an increase of +91.3% in Diluted EPS compared to the prior fiscal year.
- Shuttle Pharmaceuticals Holdings, Inc. reported Total Assets of $10.48 million for fiscal year 2025.
- Shuttle Pharmaceuticals Holdings, Inc. showed an increase of +318.0% in Total Assets compared to the prior fiscal year.
- Shuttle Pharmaceuticals Holdings, Inc. reported Cash and Equivalents of $334.0 thousand for fiscal year 2025.
- Shuttle Pharmaceuticals Holdings, Inc. showed a decrease of -82.6% in Cash and Equivalents compared to the prior fiscal year.
- Shuttle Pharmaceuticals Holdings, Inc. reported Stockholders Equity of $2.25 million for fiscal year 2025.
- Shuttle Pharmaceuticals Holdings, Inc. showed an increase of +217.9% in Stockholders Equity compared to the prior fiscal year.
- Shuttle Pharmaceuticals Holdings, Inc. reported R&D Expense of $4.05 million for fiscal year 2025.
- Shuttle Pharmaceuticals Holdings, Inc. showed an increase of +12.0% in R&D Expense compared to the prior fiscal year.
- Shuttle Pharmaceuticals Holdings, Inc. reported Operating Income of -$11.92 million for fiscal year 2025.
- Shuttle Pharmaceuticals Holdings, Inc. showed a decrease of -54.8% in Operating Income compared to the prior fiscal year.
- Shuttle Pharmaceuticals Holdings, Inc. reported Shares Outstanding of 2.02 million shares for fiscal year 2025.
- Shuttle Pharmaceuticals Holdings, Inc. showed an increase of +1140.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: